Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.19.3
Commitments and Contingencies (Details Narrative)
3 Months Ended 9 Months Ended
Jul. 31, 2019
Nov. 03, 2018
USD ($)
Sep. 12, 2018
USD ($)
Aug. 20, 2018
USD ($)
Jun. 14, 2018
USD ($)
Apr. 05, 2018
USD ($)
Apr. 05, 2018
EUR (€)
Apr. 02, 2018
Mar. 22, 2018
USD ($)
Jul. 09, 2017
USD ($)
Jun. 14, 2017
USD ($)
Sep. 14, 2015
USD ($)
Dec. 24, 2013
USD ($)
Sep. 30, 2019
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Research and development costs                           $ 570,601   $ 3,454 $ 699,038 $ 70,249
Unamortized balance of the retainer payment classified as a non-current asset                           $ 2,293    
Accreted charges                                   25,000
Reversal of accreted charges                             25,000      
NDA Consulting Corp [Member]                                    
Agreement term                         1 year          
Consulting and advisory fee                         $ 4,000 4,000   4,000 12,000 12,000
Clinical Trial Research Agreement [Member]                                    
Research and development costs                                 23,249  
Clinical Trial Research Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member]                                    
Research and development costs                           9,996     23,249  
Collaboration Agreement [Member]                                    
Research and development costs                                 87,471  
Collaboration Agreement [Member] | BioPharmaWorks LLC [Member]                                    
Research and development costs                           30,000   0 70,000 10,000
Consulting and advisory fee                       $ 10,000            
Collaboration Agreement [Member] | Grupo Espanol de Investigacion en Sarcomas [Member]                                    
Research and development costs                           87,471     87,471  
Collaboration agreement description Effective as of July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with GEIS to carry out a clinical trial entitled "Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcoma". The Company estimates that this clinical trial will be completed and results will be published by December 2022.                                  
Clinical Trial Agreement [Member]                                    
Aggregate commitments expected                           4,900,000     $ 4,900,000  
Aggregate commitments expected, description                                 The Company's aggregate commitments pursuant to these clinical trial agreements, less amounts previously incurred to date under these agreements, totaled approximately $4,900,000 as of September 30, 2019, which are expected to be incurred over the next five years through 2024.  
Work Order Agreement [Member]                                    
Research and development costs                                 $ 63,588  
Work Order Agreement [Member] | Theradex Systems, Inc [Member]                                    
Research and development costs     $ 954,000                     3,190     51,683  
Payment expected dividend for pass-through costs, description     The clinical trial is expected to be completed over a period of two years, with final analysis and reporting expected within three years. Costs under this work order agreement are estimated to be approximately $954,000, with such payments expected to be divided approximately 94% to Theradex for services and approximately 6% for payments for pass-through costs                              
Material Transfer Agreement [Member] | INSERM [Member] | Development Milestones [Member] | Maximum [Member]                                    
Milestone payments                 $ 1,750,000                  
Material Transfer Agreement [Member] | INSERM [Member] | Commercial Milestones [Member] | Maximum [Member]                                    
Milestone payments                 $ 6,500,000                  
Consulting Agreement with Liberi Life Consultancy BV [Member]                                    
Agreement term               2 years                    
Payment of a fixed, one-time retainer one time retainer           $ 18,348                        
Net payments of sales of products or licensing activities, percentage           2.50% 2.50%                      
Consulting Agreement with Liberi Life Consultancy BV [Member] | EURO [Member]                                    
Payment of a fixed, one-time retainer one time retainer | €             € 15,000                      
Consulting Agreement [Member]                                    
Amortizing the retainer payment                           2,294   2,294 6,881 4,587
Unamortized balance of the retainer payment                           4,587 11,468   $ 4,587  
Unamortized balance of the retainer payment classified as a current asset                             9,175      
Unamortized balance of the retainer payment classified as a non-current asset                             $ 2,293      
Royalties description                                 The Company will be obligated to pay Moffitt earned royalties of 4% on worldwide cumulative net sales of royalty-bearing products, subject to reduction to 2% under certain circumstances, on a quarterly basis, with a minimum royalty payment of $50,000 in the first four years after sales commence, and $100,000 in year five and each year thereafter, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term is defined in the License Agreement.  
Exclusive License Agreement [Member]                                    
Amount charges to operations                           $ 31,301     $ 74,368  
Exclusive License Agreement [Member] | First Four Years [Member]                                    
Minimum payments for royalties                                 50,000  
Exclusive License Agreement [Member] | Five Years and Thereafter [Member]                                    
Minimum payments for royalties                                 $ 100,000  
Exclusive License Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member]                                    
Non-refundable license issue fee       $ 25,000                            
Clinical trial analysis expected term       2 years                            
Clinical trial final analysis expected term       3 years                            
Annual license maintenance fee       $ 25,000                            
Payments on non-refundable milestone       $ 1,897,000                            
Percentage of milestone       40.00%                            
Materials Cooperative Research and Development Agreement [Member]                                    
Research and development costs                               $ 0   $ 25,000
Funds provide for use in acquiring technical, statistical and administrative support for research activities                     $ 100,000              
Materials Cooperative Research and Development Agreement [Member] | First Installment [Member]                                    
Paid two equal installments                   $ 50,000                
Materials Cooperative Research and Development Agreement [Member] | Second Installment [Member]                                    
Paid two equal installments         $ 50,000                          
Cancellation of installment, amount   $ 50,000